Lupin receives EIR from U.S. FDA for its Mandideep Unit-2 Manufacturing Facility

Global pharma major Lupin Limited (Lupin) has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Mandideep Unit-2 manufacturing facility. The EIR was issued post the last inspection of the facility conducted from August 7 to August 11, 2023. The inspection closed with the facility receiving an inspection classification of "No Action Indicated" (NAI).

"We are pleased to receive the EIR with a satisfactory inspection status from the U.S. FDA for the recent inspection of our Mandideep Unit-2 facility. This accomplishment is in line with our continued focus and commitment to becoming best-in-class in quality and compliance, and enables us to continue delivering quality affordable healthcare solutions globally," said Nilesh Gupta, Managing Director, Lupin.

Shares of Lupin Limited was last trading in BSE at Rs. 1128.40 as compared to the previous close of Rs. 1140.25. The total number of shares traded during the day was 15680 in over 922 trades.

The stock hit an intraday high of Rs. 1166.95 and intraday low of 1113.00. The net turnover during the day was Rs. 17822384.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 EIR USFDA Mandideep Unit2